Generic placeholder image

Current Psychiatry Reviews

Editor-in-Chief

ISSN (Print): 1573-4005
ISSN (Online): 1875-6441

N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder

Author(s): Fabiele M. Fritzen and Michael H. Bloch

Volume 10, Issue 4, 2014

Page: [308 - 316] Pages: 9

DOI: 10.2174/1573400510666140807005327

Price: $65

Abstract

Many children and adults with Obsessive-Compulsive Disorder experience incomplete symptom relief despite treatment with several evidence-based interventions for OCD. Converging lines of evidence from genetic, neuroimaging, biochemical and pharmacological studies implicate the importance of abnormalities in the glutamate symptoms in the pathogenesis of OCD. Strong evidence suggests that oxidative stress may be important in the progression of several psychiatric disorders, especially psychotic and affective disorders. N-acetylcysteine (NAC) is a cheap, relatively safe over-the-counter supplement that crosses the blood-brain barrier and acts potentially as a glutamate modulating agent and antioxidant. NAC has demonstrated efficacy in the treatment of a wide variety of psychiatric conditions in individual randomized, controlled trials including psychosis, autism, bipolar depression, trichotillomania. A recent double-blind placebo-controlled in adults with SRI-refractory OCD demonstrated the efficacy of NAC compared to placebo. In this review we summarize the preclinical and clinical data demonstrating NAC is a potentially promising new pharmacological agent in the treatment of OCD.

Keywords: Glutamate, n-acetylcysteine, obsessive-compulsive disorder, oxidative stress, review, treatment.


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy